Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: FLARE

Bringing Consistency to Gout Terms & Concepts

Larry Beresford  |  November 2, 2020

The umbrella term crystalline disease covers arthritic conditions caused by deposition of crystals and associated inflammatory response, including erythema, edema and intense pain. The two most common crystal-induced arthropathies are gout, an arthritis secondary to inflammation caused by the presence of monosodium urate (MSU) crystals formed through high levels of serum urate, and calcium pyrophosphate…

Filed under:Clinical Criteria/GuidelinesConditionsGout and Crystalline Arthritis Tagged with:Gout

Rheumatology Health Educators Educate & Empower Patients

Linda Childers  |  October 19, 2020

As a health educator at Integrative Rheumatology, a private practice in Charlotte, N.C., Latisha Williams, MPH, CHES, CHC, works with patients to teach them how to better manage their disease. In the two-and-a-half years that Ms. Williams has worked at Integrative Rheumatology, she’s answered countless questions about exercise, nutrition and complementary therapies, among other topics. “Patients…

Filed under:Patient PerspectivePractice Support Tagged with:Association of Rheumatology Professionals (ARP)health educationpatient education

G-Stock Studio / shutterstock.com

Conquering Systemic Racism in Medicine

Kimberly Retzlaff  |  October 19, 2020

2020 has not only borne witness to a global pandemic, but also to increasing fervor in the fight for racial equity. In a wave of opposition to the systemic racism in the U.S., people have been in the streets demonstrating and protesting against social injustice and have taken to social media to promote political action….

Filed under:EthicsProfessional Topics Tagged with:biasraceracial disparities

ACR Comments Help Inform ICER Assessment of Treatments for Lupus Nephritis & Other Rheumatic Conditions

Mary Beth Nierengarten  |  October 19, 2020

The ACR submitted comments to the Institute for Clinical & Economic Review outlining key considerations that should inform independent assessment of the efficacy and cost-effectiveness of medical therapies for lupus nephritis.

Filed under:American College of Rheumatology Tagged with:Dr. Chris PhillipsDr. Douglas WhiteInstitute for Clinical and Economic Review (ICER)Lupus nephritis

FDA Approves Tofacitinib for Young Patients with Active Polyarticular JIA

Michele B. Kaufman, PharmD, BCGP  |  October 9, 2020

Tofacitinib is now FDA approved to treat patients 2 years and older with active, polyarticular juvenile idiopathic arthritis.

Filed under:Drug Updates Tagged with:FDApolyarticular juvenile idiopathic arthritis (JIA)TofacitinibU.S. Food and Drug Administration (FDA)

PCSK9 Inhibitors May Lower Cholesterol in Patients with Statin-Associated Immune-Mediated Necrotizing Myopathy

Vanessa Caceres  |  September 23, 2020

A 2019 study demonstrated the benefit of a newer drug class, PCSK9 inhibitors, to help lower cholesterol in patients with statin-associated immune-mediated necrotizing myopathy…

Filed under:Drug UpdatesResearch Rheum Tagged with:Arthritis & Rheumatologycholesterolimmune-mediated necrotizing myopathyPCSK9 inhibitorsprotein convertase subtilisin/kexin type 9 inhibitorsstatin-associated myopathy

Monthly Belimumab Infusions Preserve Kidney Function in Some Lupus Patients

Reuters Staff  |  September 21, 2020

(Reuters Health)—Intravenous belimumab combined with standard lupus therapy can help preserve kidney function in patients with active lupus nephritis and cut the odds of death or a renal-related event by half, a phase 3 multinational study has concluded.1 After two years of therapy, 43% of 224 volunteers getting the drug monthly showed a renal response…

Filed under:Drug Updates Tagged with:belimumabkidneyLupus nephritisSLEsystemic lupus erythematosus (SLE)

New Classification Criteria Describe Several Hereditary Fevers

Larry Beresford  |  September 21, 2020

Evidence-based classification criteria for rare, hereditary, autoinflammatory fevers have been developed to aid clinicians in better understanding the differences between these rare conditions.

Filed under:Conditions Tagged with:ClassificationClassification CriteriaFamilial Mediterranean feverfeverheredity

Ethics Forum: The Ethical Considerations of Prior Authorization

Christina Schutt, DO, FAAP  |  September 17, 2020

The mother of a 15-year-old patient with juvenile idiopathic arthritis/enthesitis-related arthritis (JIA/ERA) called the office in tears. She said she was having an insurance problem. Her son had been a star track athlete when he developed severe back pain. Magnetic resonance imaging showed evidence of severe sacroiliitis. He was started on a tumor necrosis factor…

Filed under:EthicsInsurance Tagged with:EthicsEthics Foruminsuranceprior authorization

Drug Stoppages Often Feasible, but Patient Anxiety Can Be a Hurdle

Thomas R. Collins  |  September 11, 2020

Editor’s note: EULAR 2020, the annual European Congress of Rheumatology, which was originally scheduled to be held in Frankfurt, Germany, starting June 3, was moved to a virtual format due to the COVID-19 pandemic. EULAR 2020 e-CONGRESS—Although reducing medications is a reasonable option for some patients with rheumatoid arthritis (RA)—reducing cost and giving them a…

Filed under:ConditionsPatient PerspectiveRheumatoid Arthritis Tagged with:drug stoppageEULARreducing medicationtapering

  • « Previous Page
  • 1
  • …
  • 29
  • 30
  • 31
  • 32
  • 33
  • …
  • 68
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences